Invention Grant
- Patent Title: Immune effector cells pre-infected with oncolytic virus
-
Application No.: US14792424Application Date: 2015-07-06
-
Publication No.: US10064893B2Publication Date: 2018-09-04
- Inventor: Christopher H. Contag , Stephen H. Thorne
- Applicant: The Board of Trustees of the Leland Stanford Junior University
- Applicant Address: US CA Stanford
- Assignee: The Board of Trustees of the Leland Stanford Junior University
- Current Assignee: The Board of Trustees of the Leland Stanford Junior University
- Current Assignee Address: US CA Stanford
- Agency: Bozicevic, Field & Francis LLP
- Agent Pamela J. Sherwood
- Main IPC: A61K35/17
- IPC: A61K35/17 ; C12N5/0783 ; A61K39/00 ; A61K48/00 ; A61K35/12 ; A61K35/13
Abstract:
Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.
Public/Granted literature
- US20150320800A1 Immune Effector Cells Pre-Infected with Oncolytic Virus Public/Granted day:2015-11-12
Information query
IPC分类:
